Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks is attractive fundamentally because its hybrid, capital-efficient model combines partner-funded development, retained milestones and royalties, and recurring commercial cash flows, reducing the capital burden while preserving upside from pipeline success. The FDA approval of zanidatamab in 1L GEA, along with HERIZON-GEA-01 showing median PFS of 12.4 months and median OS of 26.4 months for the triplet, materially de-risks the lead asset and supports meaningful royalty growth from a large HER2+ market. Its balance sheet and portfolio optionality are further strengthened by a pro-forma cash position of $572.5MM, a $250M milestone payment, the Theravance acquisition, and clinical progress in ZW191, ZW251, and ZW209 that keeps the R&D engine productive.

Zymeworks is vulnerable to a weak commercial rollout for zanidatamab, which in the bear case drives only a 10% probability of success in global royalties and milestones for BTC and GEA and eliminates any platform value, sharply undermining intrinsic worth. Its outlook is further pressured by the inherently high failure rate of clinical development, the capital intensity of drug discovery, and the possibility that competing therapies or lack of clearly differentiated data reduce sales potential across its programs. In addition, regulatory timing and approval uncertainty from the FDA, combined with broader biotech sector risk, could depress the stock even if the company meets operational expectations.